Definium’s LSD Tablet Clears a Third Phase 3, With a Design Aimed at the Blinding Problem
Definium’s LSD tablet has now cleared a third Phase 3 trial this year. This one was built to answer the question critics keep raising about psychedelic research. Do patients simply know they got the drug? FirstWord Pharma reported the Panorama results on September 14, one day before FDA’s public hearing on psychedelics.
A six-hour dosing day is a staffing decision long before it is a clinical one. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The trial | Panorama, a Phase 3 study of DT120 in generalized anxiety disorder, 245 participants at about 32 centers |
| The result | Anxiety scores fell 9.8 points on the 100 µg dose versus 4.7 on placebo at week 12 |
| The effect size | A 5.1-point placebo-adjusted difference, with a Cohen’s d of 0.64 |
| The design twist | A 50 µg arm was added to make it harder for participants to guess their assignment |
| The clinic cost | 68 percent experienced illusions on dosing day, 37 percent nausea, 24 percent headache |
| What is next | A pre-NDA meeting in late 2026 and an NDA filing expected in the first half of 2027 |
What Panorama Found
The 100 µg dose of DT120, an orally disintegrating tablet of lysergide, met its primary endpoint. Hamilton Anxiety Rating Scale scores fell 9.8 points from baseline, compared with 4.7 points on placebo.
That is a placebo-adjusted difference of 5.1 points at week 12, with a Cohen’s d of 0.64. The trial enrolled 245 people across roughly 32 study centers.
It follows the Voyage trial in August, which showed a 5.4-point difference. We covered that result in our earlier piece on DT120.
The Low-Dose Arm Was the Point
The most important part of Panorama was not the headline dose. Definium added a 50 µg arm specifically to mitigate functional unblinding.
Functional unblinding is the core weakness of psychedelic trials. A participant with strong perceptual effects can usually tell they did not get placebo. Expectation can then inflate the result.
A lower active dose muddies that guess. The 50 µg arm was not powered for formal comparison, but Definium reported a dose-response pattern across the three groups.
What Analysts Took From It
RBC Capital Markets analyst Brian Abrahams spoke to Investor’s Business Daily. He said the pattern should remove lingering concerns that the effect was purely functional unblinding.
That is an analyst read, not an FDA finding. A trend across an unpowered arm is supportive evidence rather than proof.
It is still the most direct response the field has produced to the blinding criticism. The problem has run through recent coverage, including our look at psychedelic trial methods.
Why the Timing Matters
The results landed a day before FDA’s Part 15 hearing on psychedelic medicine. At that hearing, Dartmouth’s Amber Barnato described the evidence base as drawn from small, functionally unblinded trials. We covered what that hearing signaled for clinics.
FDA officials have separately said they are open to comparators other than inert placebo that may help maintain blinding. Panorama’s design is one version of that idea.
A different version compares against a sedative instead, as in the recent midazolam-controlled ketamine trial in bipolar depression.
The Secondary Endpoints Held
The 100 µg dose met all three key secondary endpoints. Anxiety scores improved 5.3 points more than placebo at week 1.
Clinical Global Impression-Severity scores improved faster too. The change was 1.1 points versus 0.3 on placebo at day 2, and 1.0 versus 0.5 at week 12.
Speed matters here. A single dose producing measurable change within two days is the commercial case for this drug.
The Dosing Day Has a Cost
Definium described DT120 as generally well tolerated. Most adverse events were mild to moderate, transient, and occurred on the day of dosing. There were no signals of suicidality.
The dosing-day profile is still significant. At 100 µg, 68 percent of participants experienced illusions, 37 percent nausea and 24 percent headache.
Those are monitoring requirements. A clinic delivering this drug needs space and staff for a long supervised session. We mapped that constraint in our piece on session length.
Psychiatrists Are Not Sold Yet
A FirstWord poll of US psychiatrists found real interest alongside real hesitation. Post-dose monitoring was one concern.
The other was the possibility of having to stop background medications before treatment. For patients stable on antidepressants, that is a serious ask.
Trial investigator Scott Aaronson framed the upside differently. He said a single dose could hold a response for months, with no daily pill to manage.
What Comes Next
Definium plans a pre-NDA meeting with FDA in the fourth quarter of 2026. It expects to file an NDA for generalized anxiety disorder in the first half of 2027.
Panorama continues into a 40-week open-label extension, which will show how long responses last. Definium’s announcement has the full endpoint list.
DT120 also succeeded in the EMERGE Phase 3 trial in major depressive disorder in June.
The Bottom Line
DT120 now has three Phase 3 wins in one year. One was designed around the field’s biggest methodological objection. That puts it near the front of the approval line.
The clinical question is largely answered. The operational one is not. A high rate of dosing-day illusions means supervised sessions, and the staffing that comes with them.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or investment advice. DT120 is an investigational drug and is not approved by the FDA.
